TICKERNERD
Menu
LGNDLGNDHealthcare · Biotechnology

LGND Stock Forecast: Ligand Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$303
+0.07% on the day

The 11 Wall Street analysts covering Ligand Pharmaceuticals, Inc. hold a median 12-month price target of $345 — +13.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 3 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$6.0B
Ticker Nerd rank
70 / 100
Median analyst target
$345
Analysts covering
11
Revenue$63.7M+33.7% y/y
Operating income$8.6M
Net income$48.5M
Free cash flow$21.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.5%
1M
+5.6%
YTD
+60.2%
1Y
+68.2%
From 52W high
−6.1%
From 52W low
+70.5%
$178
$323
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LGND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ligand Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Growth
95
Quality
94
Volatility
81
Value
73
Revisions
53
Accruals
24
Size
20
Issuance
13

Momentum (97): The shares have been drifting up relative to others.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LGND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LGND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400Jan 26Apr 26Jul 26Oct 26LGNDHigh $397Median $345Low $247

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $247Median $345High $397

The green dot is the last close — the median target sits +13.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
25 Sept 2026BarclaysInitiatesOverweight$345
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$358
23 Sept 2026CitigroupMaintainsBuy$390 → $397
14 Aug 2026Leerink PartnersInitiatesOutperform$330
14 Aug 2026Leerink PartnersInitiatesOutperform—
7 Aug 2026RBC CapitalMaintainsOutperform$340 → $345
7 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$289 → $358
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026OppenheimerReiteratesOutperform—
3 Aug 2026OppenheimerReiteratesOutperform$285 → $326
21 July 2026CitigroupReinstatesBuy$387
15 July 2026RBC CapitalMaintainsOutperform—
15 July 2026RBC CapitalMaintainsOutperform$262 → $340
9 July 2026B of A SecuritiesMaintainsBuy—
9 July 2026B of A SecuritiesMaintainsBuy$266 → $388
8 July 2026StifelMaintainsBuy—
8 July 2026StifelMaintainsBuy$255 → $332
8 May 2026RBC CapitalMaintainsOutperform—
30 Apr 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LGND appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LGND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Ligand Pharmaceuticals, Inc. returned +68.2% against +16.2% for the S&P 500, dividends included.

LGND vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26LGNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LGND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.2%
Analysts raising
4
Analysts cutting
2
Fundamentals

Ligand Pharmaceuticals, Inc. (LGND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.9×

Cheaper than 24% of US stocks

Price / sales
20.8×

Cheaper than 9% of US stocks

Price / book
6.2×

Cheaper than 16% of US stocks

EV / EBITDA
43.7×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
33.7%

Higher than 80% of US stocks

Earnings growth (YoY)
900.8%

Higher than 97% of US stocks

Gross margin
95.0%

Higher than 98% of US stocks

Operating margin
13.5%

Higher than 70% of US stocks

Net margin
67.9%

Higher than 98% of US stocks

Returns & dividend
Return on equity
22.0%

Higher than 83% of US stocks

Return on assets
4.0%

Higher than 71% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ligand Pharmaceuticals, Inc. (LGND) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ligand Pharmaceuticals, Inc. has a market value of $6.0B and an enterprise value of $5.8B.

  • Revenue in the twelve months to 30 June 2026: $290.5M. The latest quarter grew 33.7% year on year.

  • Net income over the same four quarters: $197.2M, a 67.9% net margin.

  • Diluted earnings per share, trailing twelve months: $9.35.

  • Free cash flow in the twelve months to 30 June 2026: $119.8M.

  • Shares outstanding: 19.9M.

  • Trailing P/E: 31.9×; forward P/E: 25.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ligand Pharmaceuticals, Inc. employs 47 people — $6.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

LGND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LGNDLigand Pharmaceuticals, Inc.$6.0B
70
CGONCG Oncology, Inc.$5.9B
17
SRRKScholar Rock Holding Corp.$5.7B
35
KODKodiak Sciences, Inc.$5.7B
49
IOVAIovance Biotherapeutics, Inc.$6.3B
91
ORKAOruka Therapeutics, Inc.$5.6B
40
RYTMRhythm Pharmaceuticals, Inc.$6.4B
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ligand Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LGND news & analysis

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

GlobeNewsWire · 24 Sept 2026positive

Ligand Pharmaceuticals announced a financing agreement with AvenCell Therapeutics, a clinical-stage cell therapy company developing allogeneic CAR-T therapies for cancer, for up to $47 million. The agreement is intended to advance AvenCell's pipeline of next-generation CAR-T therapies.

Why it matters — The deal expands Ligand's involvement in the cell therapy space and could generate meaningful financing-related returns as AvenCell's next-generation CAR-T programs advance.

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Business Wire · 22 Sept 2026positive

Sydnexis announced a royalty agreement with Ligand Pharmaceuticals in which Ligand will pay $23 million upfront to acquire a 100% interest in certain royalty payments associated with net sales of Ryjunea in Europe, the Middle East, and Africa.

Why it matters — This agreement provides Ligand with a newly acquired royalty interest in EMEA sales of Ryjunea, expanding its portfolio of revenue-generating assets.

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

PRNewsWire · 22 Sept 2026neutral

Primrose Bio, a provider of production solutions for next-generation biologics, announced the closing of a financing round led by new investor Signet Healthcare Partners, with participation from existing investors including Ligand Pharmaceuticals.

Why it matters — Ligand, as an existing investor in Primrose Bio, participated in this financing round, making the company's capital raise relevant to those following Ligand's investment portfolio.

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

GlobeNewsWire · 22 Sept 2026positive

Ligand Pharmaceuticals acquired an ascending tiered royalty and milestone interest in Santen's Ryjunea from Sydnexis for $23 million. The deal gives Ligand a tiered low-double-digit to high-teens royalty on Ryjunea net sales across Europe, the Middle East, and Africa. Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients.

Why it matters — This acquisition adds a new royalty-based revenue stream to Ligand's portfolio tied to a first-of-its-kind pediatric myopia treatment approved in major markets, which could benefit LGND watchers tracking the company's royalty model.

Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Seeking Alpha · 18 Sept 2026positive

Seeking Alpha reassesses Ligand Pharmaceuticals after a roughly 10% decline since its prior 'Buy' rating, focusing on its future prospects and key royalty-producing assets. LGND is characterized as a reliable midcap pharma with a high-growth business model.

Why it matters — LGND watchers would care because the piece reaffirms the strength of the company's royalty portfolio and high-growth positioning despite recent share price weakness.

FAQ

Frequently asked questions about LGND stock

What is the LGND stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Ligand Pharmaceuticals, Inc. have a median 12-month price target of $345, with estimates ranging from $247 to $397. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LGND stock a buy right now?

Of the 11 analysts covering Ligand Pharmaceuticals, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ligand Pharmaceuticals, Inc. 70 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LGND?

As at 3 Oct 2026, Ligand Pharmaceuticals, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will LGND stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +13.9% from the last close, and Ticker Nerd's factor model ranks Ligand Pharmaceuticals, Inc. 70 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LGND stock forecast for 2030?

No analyst covering Ligand Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $247 to $397 over the next 12 months.

How has LGND stock performed over the past year?

Ligand Pharmaceuticals, Inc. returned +68.2% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ligand Pharmaceuticals, Inc. do?

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing technologies and assets that support the discovery and development of medicines. Ligand Pharmaceuticals Incorporated operates a royalty-driven business model, partnering with other biopharmaceutical companies to finance and advance late-stage clinical programs while also managing a broad portfolio of royalty interests.

What is the latest news on LGND?

The most recent item we track (GlobeNewsWire, 24 Sept 2026): "Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million". Ligand Pharmaceuticals announced a financing agreement with AvenCell Therapeutics, a clinical-stage cell therapy company developing allogeneic CAR-T therapies for cancer, for up to $47 million. The agreement is intended to advance AvenCell's pipeline of next-generation CAR-T therapies.

Company

About Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing technologies and assets that support the discovery and development of medicines. Ligand Pharmaceuticals Incorporated operates a royalty-driven business model, partnering with other biopharmaceutical companies to finance and advance late-stage clinical programs while also managing a broad portfolio of royalty interests. Its current portfolio spans commercial, clinical, and preclinical-stage assets across multiple therapeutic areas, including infectious diseases, oncology, respiratory conditions, kidney disease, and rare diseases. The company also works through technology licensing and asset acquisition activities to expand the range of medicines connected to its platform. Based in Jupiter, Florida, Ligand Pharmaceuticals Incorporated plays a specialized role in the life sciences market by providing capital, expertise, and royalty management across a diversified set of partnered drug programs.

CEO Mr. Todd C. Davis Ph.D. · 47 employees · United States · https://www.ligand.com